Granules India Limited — Updates, 08-11-2024: Press Release

Granules India Limited has received a favorable Establishment Inspection Report (EIR) from the U.S. FDA for its Unit V facility in Andhra Pradesh, indicating compliance with Good Manufacturing Practices (cGMP) standards. The inspection resulted in "No Action Indicated" status, confirming zero observations and reflecting the company’s commitment to high-quality production of pharmaceutical products. This milestone enhances Granules India's efforts to provide accessible and quality pharmaceuticals globally.